e8vk
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 22, 2004

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)
         
Delaware   0-24274   33-0361285
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
6455 Nancy Ridge Drive, San Diego, California   92121
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 452-6600

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

TABLE OF CONTENTS

Item 8.01. Other Events.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
EXHIBIT 99.1

Table of Contents

Item 8.01. Other Events.

     On September 22, 2004, La Jolla Pharmaceutical Company issued a press release announcing that Steven Engle, the Company’s Chief Executive Officer, will present at the UBS Global Life Sciences Conference on September 30, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

     (c) Exhibits. The following exhibits are filed with this report on Form 8-K:

     
Exhibit    
Number
   Description of Exhibit
99.1
  Press Release

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    LA JOLLA PHARMACEUTICAL COMPANY
 
        
Date: September 22, 2004
  By:   /s/ Steven B. Engle
     
 
      Steven B. Engle
Chairman and Chief Executive Officer

 

Table of Contents

EXHIBIT INDEX

     
Exhibit    
Number
   Description of Exhibit
99.1
  Press Release